Startseite>>Signaling Pathways>> Neuroscience>> Ophthalmology>>Prostaglandin F2α methyl ester

Prostaglandin F2α methyl ester (Synonyms: PGF2α methyl ester)

Katalog-Nr.GC18370

Prostaglandin F2α methyl ester (PGF2α methyl ester) is an analog of PGF2α in which the C-1 carboxyl group has been esterified as the methyl ester.

Products are for research use only. Not for human use. We do not sell to patients.

Prostaglandin F2α methyl ester Chemische Struktur

Cas No.: 33854-16-9

Größe Preis Lagerbestand Menge
500μg
44,00 $
Auf Lager
1mg
83,00 $
Auf Lager
5mg
342,00 $
Auf Lager
10mg
602,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products
Prostaglandin F2α methyl ester (PGF2α methyl ester) is an analog of PGF2α in which the C-1 carboxyl group has been esterified as the methyl ester. PGF2α methyl ester was one of the first PG esters shown to have ocular hypotensive activity. This compound continues to be a standard by which other ocular hypotensive PG prodrugs are evaluated. The methyl ester is about 4-5 times more potent than the free acid, PGF2α. This difference is attributed to improved corneal penetration, and a depot effect of prolonged retention of the ester form of the compound in ocular tissue. A 2.5 ug dose of PGF2α-OMe applied to the eyes of cats results in a 6-8 mm Hg reduction in IOP.

Bewertungen

Review for Prostaglandin F2α methyl ester

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Prostaglandin F2α methyl ester

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.